The erectile–endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention

Abstract

Erectile and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors and are longitudinal predictors of cardiovascular events. The pathogenesis of both endothelial and erectile dysfunction is intimately linked through increased expression and activation of endothelial nitric oxide synthase, and the subsequent physiological actions of nitric oxide. Endothelial production of nitric oxide by endothelial nitric oxide synthase in the corpus cavernosum is involved in the maintenance of penile erection. Erectile dysfunction can be detected clinically using systematic questioning and could potentially be employed as an independent predictor of cardiovascular risk to target treatment of cardiovascular risk factors. Both erectile and endothelial dysfunction respond to lifestyle modifications, particularly in individuals with the metabolic syndrome. Drugs that improve endothelial dysfunction can also improve erectile dysfunction, but responses are not always concordant. Phosphodiesterase type 5 inhibitors, however, are powerful agents that commonly improve erectile and endothelial dysfunction, with potential cardiac applications. The recent Princeton consensus requires more extensive implementation and evaluation in clinical practice. The judicious diagnosis of erectile dysfunction, nevertheless, provides a unique opportunity for the prevention of cardiovascular disease.

Key Points

  • Endothelial and erectile dysfunction are intimately associated; both disorders arise from disturbance in the release and action of nitric oxide from endothelial cells

  • Erectile and endothelial dysfunction can be readily detected clinically and are associated with a wide spectrum of cardiovascular risk factors, and are also independently predictive of cardiovascular events

  • Both conditions can be improved by lifestyle modifications and by several pharmacological agents

  • Phosphodiesterase type 5 inhibitors improve both endothelial and erectile dysfunction by potentiating the action of nitric oxide from endothelial cells

  • The Princeton consensus offers practical guidelines for assessing cardiovascular risk in patients with erectile dysfunction and managing erectile dysfunction in patients with established coronary artery disease

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: The physiology of penile erection—peripheral mechanisms
Figure 2: The roles of two forms of nitric oxide synthase in cavernosal smooth muscle relaxation and the initiation and maintenance of penile erection
Figure 3: The prevalence of erectile dysfunction, estimated by the IIEF-5 score, and serum high-sensitivity CRP levels in relation to components of the metabolic syndrome, as defined by the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Figure 4: The 'artery size' hypothesis
Figure 5: Mechanism of action of phosphodiesterase type 5 inhibitors in inducing smooth-muscle relaxation in cavernosal arteries and in the peripheral circulation

References

  1. 1

    NIH Consensus Development Panel on Impotence (1993) Impotence. JAMA 270: 83–90

  2. 2

    Shabsigh R and Anastasiadis AG (2003) Erectile dysfunction. Annu Rev Med 54: 153–168

    CAS  Article  Google Scholar 

  3. 3

    Montorsi P et al. (2004) Common grounds for erectile dysfunction and coronary artery disease. Curr Opinion Urol 14: 361–365

    Article  Google Scholar 

  4. 4

    Corbin JD et al. Phosphodiesterase-5 inhibitors: importance to the cardiovascular system. In Contemporary Cardiology: Heart Disease and Erectile Dysfunction, 117–137 (Ed Kloner RA) Totowa: Humana Press Inc.

  5. 5

    Andersson KE and Wagner G (1995) Physiology of penile erection. Physiol Rev 75: 191–236

    CAS  Article  Google Scholar 

  6. 6

    Traish AM and Guay AT (2006) Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 3: 382–407

    CAS  Article  Google Scholar 

  7. 7

    Burnett AL (1997) Nitric oxide in the penis: physiology and pathology. J Urol 157: 320–324

    CAS  Article  Google Scholar 

  8. 8

    Maas R et al. (2002) The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 7: 213–225

    Article  Google Scholar 

  9. 9

    Saenz de Tejada I et al. (2004) Physiology of erectile function. J Sex Med 1: 254–265

    CAS  Article  Google Scholar 

  10. 10

    Hurt KJ et al. (2002) Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 99: 4061–4016

    CAS  Article  Google Scholar 

  11. 11

    Burnett AL (2004) Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 16: S15–S19

    CAS  Article  Google Scholar 

  12. 12

    Solomon H et al. (2003) Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89: 251–253

    CAS  Article  Google Scholar 

  13. 13

    Bortolotti A et al. (1997) The epidemiology of erectile dysfunction and its risk factors. Int J Androl 20: 323–334

    CAS  Article  Google Scholar 

  14. 14

    Bonetti PO et al. (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168–175

    CAS  Article  Google Scholar 

  15. 15

    Cooke JP and Dzau VJ (1997) Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48: 489–509

    CAS  Article  Google Scholar 

  16. 16

    Celermajer DS et al. (1994) Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24: 1468–1474

    CAS  Article  Google Scholar 

  17. 17

    Brunner H et al. (2005) Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23: 233–246

    CAS  Article  Google Scholar 

  18. 18

    Farouque HMO and Meredith IT (2001) The assessment of endothelial function in humans. Coron Artery Dis 12: 445–454

    CAS  Article  Google Scholar 

  19. 19

    Vita JA and Keaney JF Jr (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106: 640–642

    Article  Google Scholar 

  20. 20

    Lyons D et al. (1997) Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci (Lond) 93: 519–525

    CAS  Article  Google Scholar 

  21. 21

    Cooke JP (2005) ADMA: its role in vascular disease. Vasc Med 10 (Suppl): S11–S17

    Article  Google Scholar 

  22. 22

    Katusic ZS (2001) Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 281: H981–H986

    CAS  Article  Google Scholar 

  23. 23

    Elesber AA et al. (2006) Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 27: 824–831

    CAS  Article  Google Scholar 

  24. 24

    Foresta C et al. (2005) Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res 17: 288–290

    CAS  Article  Google Scholar 

  25. 25

    Wierzbicki AS et al. (2006) Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 185: 421–425

    CAS  Article  Google Scholar 

  26. 26

    Grundy SM et al.; American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735–2752

    Article  Google Scholar 

  27. 27

    Rosen RC et al. (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11: 319–326

    CAS  Article  Google Scholar 

  28. 28

    Cappelleri JC et al. (1999) Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 54: 346–351

    CAS  Article  Google Scholar 

  29. 29

    Walczak MK et al. (2002) Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 5: 19–24

    PubMed  Google Scholar 

  30. 30

    Wei M et al. (1994) Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 140: 930–937

    CAS  Article  Google Scholar 

  31. 31

    Feldman HA et al. (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54–61

    CAS  Article  Google Scholar 

  32. 32

    Feldman HA et al. (2000) Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 30: 328–338

    CAS  Article  Google Scholar 

  33. 33

    Greenstein A et al. (1997) Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 9: 123–126

    CAS  Article  Google Scholar 

  34. 34

    Kloner RA et al. (2003) Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 170 (Suppl): S46–S50

    PubMed  Google Scholar 

  35. 35

    Solomon H et al. (2003) Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 91: 230–231

    Article  Google Scholar 

  36. 36

    Montorsi F et al. (2003) Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44: 360–364

    Article  Google Scholar 

  37. 37

    Chiurlia E et al. (2005) Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 46: 1503–1506

    Article  Google Scholar 

  38. 38

    Jackson G et al. (2006) The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 3: 28–36

    CAS  Article  Google Scholar 

  39. 39

    Esposito K et al. (2005) High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 28: 1201–1203

    Article  Google Scholar 

  40. 40

    Giugliano F et al. (2004) Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 27: 665–669

    CAS  Article  Google Scholar 

  41. 41

    Kato M et al. (2000) Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 102: 2607–2610

    CAS  Article  Google Scholar 

  42. 42

    Margel D et al. (2004) Severe, but not mild, obstructive sleep apnea syndrome is associated with erectile dysfunction. Urology 63: 545–549

    Article  Google Scholar 

  43. 43

    De Angelis L et al. (2001) Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia 44: 1155–1160

    CAS  Article  Google Scholar 

  44. 44

    Thompson IM et al. (2005) Erectile dysfunction and subsequent cardiovascular disease. JAMA 294: 2996–3002

    CAS  Article  Google Scholar 

  45. 45

    Uslu N et al. (2006) Left ventricular diastolic function and endothelial function in patients with erectile dysfunction. Am J Cardiol 97: 1785–1788

    CAS  Article  Google Scholar 

  46. 46

    Kaya C et al. (2006) Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 18: 55–60

    CAS  Article  Google Scholar 

  47. 47

    Gazzaruso C et al. (2004) Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 110: 22–26

    Article  Google Scholar 

  48. 48

    Kaiser DR et al. (2004) Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43: 179–184

    Article  Google Scholar 

  49. 49

    Bocchio M et al. (2004) Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 171: 1601–1604

    Article  Google Scholar 

  50. 50

    Stuckey BGA et al. (2006) Erectile dysfunction predicts generalized cardiovascular disease: evidence from a case-control study. Atherosclerosis [doi:10.1016/j.atherosclerosis.2006.08.043]

    Google Scholar 

  51. 51

    Montorsi P et al. (2005) The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 96 (Suppl 2): 19M–23M

    Article  Google Scholar 

  52. 52

    Bonetti PO et al. (2003) Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J 24: 225–248

    CAS  Article  Google Scholar 

  53. 53

    Woodman RJ et al. (2005) Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs 65: 31–74

    CAS  Article  Google Scholar 

  54. 54

    Esposito K et al. (2004) Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291: 2978–2984

    CAS  Article  Google Scholar 

  55. 55

    Esposito K et al. (2006) Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 18: 405–410

    CAS  Article  Google Scholar 

  56. 56

    Margel D et al. (2005) Predictors of erectile function improvement in obstructive sleep apnea patients with long-term CPAP treatment. Int J Impot Res 17: 186–190

    CAS  Article  Google Scholar 

  57. 57

    Rizvi K et al. (2002) Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 19: 95–98

    Article  Google Scholar 

  58. 58

    Bruckert E et al. (1996) Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 21: 89–94

    CAS  Article  Google Scholar 

  59. 59

    Solomon H et al. (2006) Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 60: 141–145

    CAS  Article  Google Scholar 

  60. 60

    Pedersen TR and Faergeman O (1999) Simvastatin seems unlikely to cause impotence. BMJ 318: 192

    CAS  Article  Google Scholar 

  61. 61

    Herrmann HC et al. (2006) Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 3: 303–308

    CAS  Article  Google Scholar 

  62. 62

    Speel TG et al. (2005) Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: a pilot study. J Sex Med 2: 207–212

    CAS  Article  Google Scholar 

  63. 63

    Keene LC and Davies PH (1999) Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 18: 5–24

    CAS  PubMed  Google Scholar 

  64. 64

    Fogari R et al. (2001) Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 14: 27–31

    CAS  Article  Google Scholar 

  65. 65

    Corbin JD (2004) Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 16 (Suppl 1): S4–S7

    CAS  Article  Google Scholar 

  66. 66

    Jackson G et al. (1999) Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83: 13C–20C

    CAS  Article  Google Scholar 

  67. 67

    Katz SD et al. (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36: 845–851

    CAS  Article  Google Scholar 

  68. 68

    Halcox JPJ et al. (2002) The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40: 1232–1240

    CAS  Article  Google Scholar 

  69. 69

    Ghofrani HA et al. (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary hypertension. J Am Coll Cardiol 43 (Suppl): S68–72S

    Article  Google Scholar 

  70. 70

    Desouza C et al. (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25: 1336–1339

    CAS  Article  Google Scholar 

  71. 71

    Rosano GMC et al. (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47: 214–220

    CAS  Article  Google Scholar 

  72. 72

    Hryniewicz K et al. (2005) Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (Lond) 108: 331–338

    CAS  Article  Google Scholar 

  73. 73

    Solomon H et al. (2006) Cardiovascular risk factors determine erectile and arterial function response to sildenafil. Am J Hypertens 19: 915–919

    CAS  Article  Google Scholar 

  74. 74

    DeBusk R et al. (2000) Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 86: 175–181

    CAS  Article  Google Scholar 

  75. 75

    DeBusk RF (2005) Erectile dysfunction therapy in special populations and applications: coronary artery disease. Am J Cardiol 96: 62M–66M

    Article  Google Scholar 

  76. 76

    Mittleman MA et al. (2005) Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 96: 443–446

    CAS  Article  Google Scholar 

  77. 77

    Chew KK et al. (2000) Erectile dysfunction, sildenafil and cardiovascular risk. Med J Aust 172: 279–283

    CAS  PubMed  Google Scholar 

  78. 78

    Sweeney M and Siegel RL (2004) Potential cardiac applications of phosphodiesterase type-5 inhibitors. In Contemporary Cardiology: Heart Disease and Erectile Dysfunction, 207–237 (Ed Kloner RA) Totowa: Humana Press Inc.

    Google Scholar 

  79. 79

    Bocchio M et al. (2005) Intima-media thickening of common carotid arteries is a risk factor for severe erectile dysfunction in men with vascular risk factors but no clinical evidence of atherosclerosis. J Urol 173: 526–529

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gerald F Watts.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Watts, G., Chew, K. & Stuckey, B. The erectile–endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat Rev Cardiol 4, 263–273 (2007). https://doi.org/10.1038/ncpcardio0861

Download citation

Further reading